Nessuna novità dal 16 ott UTCGiorno 1

FDA approval and access to daraxonrasib

Aggiornamento 1 di 1Ultimo29 ago, 20:21 UTCGiorno 1
FDA Approves First RAS-Targeted Pill for Metastatic Pancreatic Cancer
Daraxonrasib targets the mutation behind more than 90% of cases and nearly doubled life expectancy in its pivotal trial, a landmark for a cancer with 13% five-year survival.
Guarda
Cosa sapevamo all'inizio
- FDA approved daraxonrasib on August 26, 2026.
- Approval was based on the pivotal randomized phase 3 RASolute 302 trial.
- Drug targets mutated RAS driving more than 90% of pancreatic cancers.
- Trial showed life expectancy nearly doubled, per USA Today.
Allora ancora aperto
- No verified price, coverage terms, or out-of-pocket burden in these excerpts.
- No verified exact survival months, side-effect rates, or full label details in these excerpts.
Cosa avevamo detto di seguire
- Full RASolute 302 publication with survival, safety, and subgroup data.
- Label details, real-world tolerability, and access terms for previously treated patients.

Chi ne ha riferito

Chi ne ha riferito

9 testate · 11 fonti · 1 video

A questo punto, 0 fonti su 9 avevano pubblicato

News-Medicalnews-medical.net2
1. FDA approves first RAS-targeted therapy for metastatic pancreatic cancer
2. FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber
Pancreatic Cancer Action Networkpancan.org2
1. FDA Approves RASONQUE™ (daraxonrasib)
2. First RAS Inhibitor Extends Survival in Previously Treated Metastatic Pancreatic Adenocarcinoma: What You Need to Know
ABC Newsabcnews.com1
1. FDA approves landmark pancreatic cancer drug that's shown to improve survival
CBS Newscbsnews.com1
1. FDA approves new pancreatic cancer drug that could extend patients' lives
Forbesforbes.com1
1. FDA Approves New Pancreatic Cancer Drug After Stunning Trial Results
HeyDay News1
1. New Pancreatic Cancer Pill Doubles Survival, But Cost Excludes Medicare Patientsvideo
Reutersreuters.com1
1. Revolution's lifesaving pancreatic cancer drug wins speedy FDA approval
Scientific Americanscientificamerican.com1
1. U.S. approves breakthrough pancreatic cancer drug, heralding a new era for an intractable disease

Chi è coinvolto

Chi è coinvolto

Luoghi

Dana-Farber Cancer Institute
United States